Please assess the completion status of the following clinical trial:

Trial Title: Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MS diagnostic regarding the modified McDonald criteria~* EDSS status between 4.0 and 6.5~* patients able to walk during 6 minutes~Exclusion Criteria:~* increasing MS symptoms during the previous 60 days~* history of epilepsy or epileptic seizure~* immunotherapy change in the previous 60 days~* beginning anti-spastic treatment in the previous 30 days~* beginning treatment that is able to decrease fatigue symptoms in the previous 30 days~* modification of the rehabilitation program during the study~* renal insufficiency (creatinine clearance \<80ml.min-1 given by the Cockroft-Gault formula)~* concomitant treatment by organic cation transporter 2 inhibitor~* hypersensitivity to fampridine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Fampridine responder (Type: EXPERIMENTAL): Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine responder is a PwMS with an improvement in the judgment of the practitioner.
- Fampridine non responder (Type: ACTIVE_COMPARATOR): Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine non responder is a PwMS without any improvement in the judgment of the practitioner.

Based on this trial design, predict the completion outcome and termination type (if applicable).